ANIK

Anika Therapeutics, Inc.

Healthcare · $203M market cap

Is ANIK undervalued?

Share price

$14.55

as of Nov 7, 2026

Fair value

$5.07

Sticker Price

Payback Price

$2.03

buy price

Based on annual results to Dec 2025.

Overpriced

ANIK is Overpriced: at $14.55 it trades 187% above its fair value of $5.07. Its buy price (Payback Price) is $2.03, 86% below today's price. Business quality is limited: only 1 of 5 key numbers clears the 10% bar.

How we valued it

Free Cash Flow Growth. There's too little earnings history to value it on earnings, but it has produced free cash flow consistently, so we value it on cash flow.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth17.3% a year✓
Equity per share growth9.7% a year✗
Sales growth8.4% a year✗
Free cash flow growth4.0% a year✗
Return on invested capital-3.2%✗

Follow ANIK

Get notified when it reaches its buy price of $2.03. Free.

Create a free account

Questions about ANIK

What is ANIK's fair value?

$5.07 as of Nov 7, 2026, worked out with the Free Cash Flow Growth. There's too little earnings history to value it on earnings, but it has produced free cash flow consistently, so we value it on cash flow.

At what price would ANIK be a buy?

At or below its buy price of $2.03, a 60% margin of safety below its fair value.

Is ANIK undervalued right now?

ANIK is Overpriced: at $14.55 it trades 187% above its fair value and 617% above its buy price.

How can I check ANIK's value myself?

Use the free Sticker Price calculator, already filled with ANIK's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →

Similar stocks · Medical - Specialties

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.

Medical - Specialties

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Nov 7, 2026. How the Payback Price works

ANIK Fair Value $5.07, Buy Price $2.03 — Is ANIK Undervalued?